Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psychiatry Advisor
A meta-analysis of seven studies found cannabinoid-based therapies were associated with lower agitation and neuropsychiatric symptom scores in patients with moderate to severe Alzheimer disease. Cognitive benefits were not consistently observed, and somnolence occurred more frequently with treatment.
Geriatrics August 19th 2026
News Medical
A randomized crossover trial of 108 habitual cannabis users found fewer premature atrial contractions on cannabis-use days than abstinence days. The short-term physiologic findings provide mechanistic insight but were not designed to evaluate long-term cardiovascular health outcomes.
Cardiology August 19th 2026
Physician’s Weekly
A narrative review and accompanying expert commentary outlined diagnostic features distinguishing substance-induced psychosis from primary psychotic disorders amid rising cannabis and stimulant exposure.
Psychiatry May 27th 2026
Medical Xpress
As cannabis becomes more widely available and socially accepted and legalized in various jurisdictions, it is essential to understand its potential health risks and the need for health care professionals to routinely talk to patients about cannabis use.
Endocrinology, Diabetes, Metabolism September 15th 2025
Reclassifying marijuana from Schedule I to a lower schedule would significantly ease the regulatory burden on researchers.
Neurology February 20th 2025
Heavy cannabis users showed reduced activity in key brain regions associated with working memory, with 63% demonstrating measurable changes in cognitive function during specific tasks.
Child & Adolescent Psychiatry February 5th 2025